Product Description
Desipramine is a secondary amine tricyclic antidepressant that is FDA approved for the treatment of depression. It is not considered the first line for depression due to the several adverse effects of this drug. This drug has off-label use in the treatment of bulimia nervosa, irritable bowel syndrome, neuropathic pain, overactive bladder, postherpetic neuralgia, and ADHD. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK470581/)
Mechanisms of Action: NRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Chile | Ireland | Israel | Lebanon | New Zealand | Saudi Arabia | Taiwan | Turkey | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|